Federal Register / Vol. 76, No. 219 / Monday, November 14, 2011 / Notices 70463 

Contact Person: Jeffrey H. Hurst, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7208, Bethesda, MD 20892–7924, (301) 435– 

0303, hurstj@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: November 7, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–29311 Filed 11–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Preclinical Medications Discovery and Abuse 

Liability Testing (8904). 

Date: December 6, 2011. 

Time: 9:30 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 4227, MSC 9550, 6001 

Executive Boulevard, Bethesda, MD 20892– 

9550, (301) 435–1439, lf33c.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Purity 

Specifications, Storage and Distribution for 

Medications Development (8903). 

Date: January 4, 2012. 

Time: 9:30 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 4227, MSC 9550, 6001 

Executive Boulevard, Bethesda, MD 20892– 

9550, (301) 435–1439, lf33c.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: November 7, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–29310 Filed 11–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; NANO 

Special Panel. 

Date: December 5, 2011. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: James J. Li, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5148, 

MSC 7849, Bethesda, MD 20892, (301) 806– 

8065, lijames@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Aging and Neurodegenerative 

Disorders. 

Date: December 9, 2011. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Carol Hamelink, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4192, 

MSC 7850, Bethesda, MD 20892, (301) 213– 

9887 hamelinc@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 7, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–29307 Filed 11–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of the Secretary 

Exercise of Authority Under the 

Immigration and Nationality Act 

AGENCY: Office of the Secretary, DHS. 

ACTION: Notice of determination. 

Authority: 8 U.S.C. 1182(d)(3)(B)(i). 

Following consultations with the 

Secretary of State and the Attorney 

General, I hereby conclude, as a matter 

of discretion in accordance with the 

authority granted to me by section 

212(d)(3)(B)(i) of the Immigration and 

Nationality Act (INA), 8 U.S.C. 

1182(d)(3)(B)(i), as amended, as well as 

the foreign policy and national security 

interests deemed relevant in these 

consultations, that subsections 

212(a)(3)(B)(iv)(VI)(bb), (cc), and (dd) of 

the INA, 8 U.S.C. 

1182(a)(3)(B)(iv)(VI)(bb), (cc), and (dd), 

shall not apply with respect to the 

provision of medical care by an alien, 

provided that the alien satisfies the 

relevant agency authority that the alien: 

(a) Is seeking a benefit or protection 

under the INA and has been determined 

to be otherwise eligible for the benefit 

or protection; 

(b) Has undergone and passed all 

relevant background and security 

checks; 

(c) Has fully disclosed, to the best of 

his or her knowledge, in all relevant 

applications and interviews with U.S. 

government representatives and agents, 

the nature and circumstances of any 

medical care provided and any other 

activity or association falling within the 

scope of section 212(a)(3)(B) of the INA, 

8 U.S.C. 1182(a)(3)(B); 

mstockstill on DSK4VPTVN1PROD with NOTICES

70464 Federal Register / Vol. 76, No. 219 / Monday, November 14, 2011 / Notices 

(d) Has not voluntarily and knowingly 

provided medical care on behalf of a 

designated terrorist organization, as 

described in INA section 

212(a)(3)(B)(vi)(I) or (II); 

(e) Has not voluntarily and knowingly 

provided medical care with the intent of 

furthering the terrorist or otherwise 

violent activities of an organization or 

individual; 

(f) Poses no danger to the safety and 

security of the United States; and 

(g) Warrants an exemption from the 

relevant inadmissibility provision in the 

totality of the circumstances. 

Implementation of this determination 

will be made by U.S. Citizenship and 

Immigration Services (USCIS), in 

consultation with U.S. Immigration and 

Customs Enforcement (ICE), or by U.S. 

consular officers, as applicable, who 

shall ascertain, to their satisfaction, and 

in their discretion, that the particular 

applicant meets each of the criteria set 

forth above. 

When considering the totality of the 

circumstances, factors to be considered 

may include, among others: The 

purpose, extent, frequency, and nature 

of the medical care provided; the 

circumstances under which it was 

provided; the alien’s involvement with 

the terrorist organization, including past 

or present membership and role in the 

organization; the nature of the activities 

committed by the terrorist organization; 

the alien’s awareness of those activities; 

and the alien’s conduct since providing 

the medical care. 

This exercise of authority may be 

revoked as a matter of discretion and 

without notice at any time with respect 

to any and all persons subject to it. Any 

determination made under this exercise 

of authority as set out above can inform 

but shall not control a decision 

regarding any subsequent benefit or 

protection applications, unless such 

exercise of authority has been revoked. 

This exercise of authority shall not be 

construed to prejudice, in any way, the 

ability of the U.S. government to 

commence subsequent criminal or civil 

proceedings in accordance with U.S. 

law involving any beneficiary of this 

exercise of authority (or any other 

person). This exercise of authority 

creates no substantive or procedural 

right or benefit that is legally 

enforceable by any party against the 

United States or its agencies or officers 

or any other person. 

In accordance with section 

212(d)(3)(B)(ii) of the INA, 8 U.S.C. 

1182(d)(3)(B)(ii), a report on the aliens 

to whom this exercise of authority is 

applied, on the basis of case-by-case 

decisions by the U.S. Department of 

Homeland Security or by the U.S. 

Department of State, shall be provided 

to the specified congressional 

committees not later than 90 days after 

the end of the fiscal year. 

This determination is based on an 

assessment related to the national 

security and foreign policy interests of 

the United States as they apply to the 

particular persons described herein and 

shall not have any application with 

respect to other persons or to other 

provisions of U.S. law. 

Dated: October 13, 2011. 

Janet Napolitano, 

Secretary of Homeland Security. 

[FR Doc. 2011–29316 Filed 11–10–11; 8:45 am] 

BILLING CODE 9110–09–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of the Secretary 

[Docket No. DHS–2011–0105] 

DHS Data Privacy and Integrity 

Advisory Committee 

AGENCY: Privacy Office, DHS. 

ACTION: Committee Management; Notice 

of Federal Advisory Committee Meeting. 

SUMMARY: The DHS Data Privacy and 

Integrity Advisory Committee will meet 

on December 6, 2011, in Washington, 

DC. The meeting will be open to the 

public. 

DATES: The DHS Data Privacy and 

Integrity Advisory Committee will meet 

on Tuesday, December 6, 2011, from 

1 p.m. to 5 p.m. Please note that the 

meeting may end early if the Committee 

has completed its business. 

ADDRESSES: The meeting will be held in 

the U.S. Citizenship and Immigration 

Services Tomich Center, 111 

Massachusetts Avenue NW. (corner of 

New Jersey Avenue) Washington, DC 

20529. 

For information on facilities or 

services for individuals with 

disabilities, or to request special 

assistance at the meeting, contact 

Martha K. Landesberg, Executive 

Director, DHS Data Privacy and Integrity 

Advisory Committee, as soon as 

possible. 

To facilitate public participation, we 

invite public comment on the issues to 

be considered by the Committee as 

listed in the SUPPLEMENTARY

INFORMATION section below. A public 

comment period will be held during the 

meeting from 4 p.m. to 4:30 p.m., and 

speakers are requested to limit their 

comments to 3 minutes. If you would 

like to address the Committee at the 

meeting, we request that you register in 

advance by contacting Martha K. 

Landesberg at the address provided 

below or sign up at the registration desk 

on the day of the meeting. The names 

and affiliations, if any, of individuals 

who address the Committee are 

included in the public record of the 

meeting. Please note that the public 

comment period may end before the 

time indicated, following the last call 

for comments. Written comments 

should be sent to Martha K. Landesberg, 

Executive Director, DHS Data Privacy 

and Integrity Advisory Committee, by 

December 1, 2011. Persons who wish to 

submit comments and who are not able 

to attend or speak at the meeting may 

submit comments at any time. All 

submissions must include the Docket 

Number (DHS–2011–0105) and may be 

submitted by any one of the following 

methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• E-mail: PrivacyCommittee@dhs.gov. 

Include the Docket Number (DHS– 

2011–0105) in the subject line of the 

message. 

• Fax: (703) 483–2999. 

• Mail: Martha K. Landesberg, 

Executive Director, Data Privacy and 

Integrity Advisory Committee, 

Department of Homeland Security, 

Washington, DC 20528. 

Instructions: All submissions must 

include the words ‘‘Department of 

Homeland Security Data Privacy and 

Integrity Advisory Committee’’ and the 

Docket Number (DHS–2011–0105). 

Comments received will be posted 

without alteration at http:// 

www.regulations.gov, including any 

personal information provided. 

If you wish to attend the meeting, 

please plan to arrive at the Tomich 

Center by 12:45 p.m., to allow extra time 

to be processed through security, and 

bring a photo I.D. 

The DHS Privacy Office encourages 

you to register for the meeting in 

advance by contacting Martha K. 

Landesberg, Executive Director, DHS 

Data Privacy and Integrity Advisory 

Committee, at 

PrivacyCommittee@dhs.gov. Advance 

registration is voluntary. The Privacy 

Act Statement below explains how DHS 

uses the registration information you 

may provide and how you may access 

or correct information retained by DHS, 

if any. 

Docket: For access to the docket to 

read background documents or 

comments received by the DHS Data 

Privacy and Integrity Advisory 

Committee, go to http:// 

www.regulations.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES